| |
Tumor tissue
|
|---|
|
Plasma
|
Direct sequencing
|
|---|
| |
Wild type
|
Mutated
|
Total
|
Kappa
|
p value
†
|
|---|
|
Direct sequencing
| | | | | |
|---|
|
Wild-type (%)
|
138 (57)
|
63 (26)
|
201
|
·278
|
<0 · 001
|
|
Mutated (%)
|
11 (5)
|
30 (12)
|
41
| | |
|
Total
|
149
|
93
|
242
| | |
|
PNA-PCR
|
PNA-PCR
|
|
Wild-Type (%)
|
113 (47)
|
53 (22)
|
166
|
·456
|
<0 · 001
|
|
Mutated (%)
|
12 (5)
|
64 (26)
|
76
| | |
|
Total
|
125
|
117
|
242
| | |
- *Kappa test was used to estimate the concordance of KRAS status between tumor tissue and plasma samples.
- †All Wald statistical tests were two-sided.
- PNA-PCR, peptide-nucleic-acid-mediated polymerase chain reaction clamping.
